Hodgkin Lymphoma Clinical Trial
Official title:
The Impact of Inspiratory Muscle Strength Training and Personalized Exercise Prescription on Metabolism, Cardiovascular Function, and Cardiorespiratory Fitness in Lymphoma Survivors
High-resistance inspiratory muscle strength training (IMST) is a time-efficient (~5 minutes/day) form of exercise that employs an affordable, handheld device which impedes inspiratory breathing to train the diaphragm and accessory respiratory muscles and has demonstrated improvements in both cardiovascular health (9 mmHg reduction in systolic blood pressure, 45% improvement in vascular endothelial function) and improve exercise tolerance (12% increase in treadmill exercise time) in generally healthy midlife/older adults. Therefore, this approach may circumvent preventative hurdles to exercise, and augment the effects of exercise for capable survivors.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | January 2026 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age 18 - 80 - Primary cancer diagnosis of lymphoma - Able and willing to participate in a supervised exercise program at the Anschutz Health and Wellness Center - Provides a signed physician exercise clearance form - SBP > 120 mmHg - Completion of curative cancer treatment over 12 months prior (individuals on maintenance therapy will be included) - Possession of a smartphone compatible with the IMST training application (available on both Android and Apple). Exclusion Criteria: - oSecond active cancer diagnosis - oPlanned active cancer treatment or change in current treatment in the next 6 months - Severe obesity (BMI > 40 kg/m2) or underweight (BMI < 18.5 kg/m2) - Unstable weight (> 3 kg change in body mass in last 3 months) - Significant metabolic disorder (e.g. diabetes type II) - Uncontrolled thyroid disease - Recent changes in hypertensive medication (within last 3 months) - Greater than 100 min of self-reported regular exercise per week - Any medical condition that would impact the safety of, or participation in, an exercise program, including: - Significant pulmonary conditions such as chronic obstructive pulmonary disease, emphysema, or interstitial lung disease - Known cardiovascular disease, significant hypertension (> 180/120), or a recent cardiac event (within past 6 months) - Orthopedic conditions such as advanced osteoarthritis, mobility-limiting amputations or chronic injuries, or mobility-limiting acute orthopedic injuries - Advanced rheumatoid arthritis or chronic widespread pain conditions such as fibromyalgia |
Country | Name | City | State |
---|---|---|---|
United States | Anschutz Health and Wellness | Aurora | Colorado |
United States | University of Colorado Cancer Center | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Participants Recruited | Count of number of participants recruited into the study | 2 years | |
Primary | Enrolled Participants per Month | Average number of participants enrolled per month of the study | 2 years | |
Primary | Valid Assessments per Participant | Adherence to 75% of the program will be deemed acceptable | 5 months | |
Primary | Session Attendance per Participant | Adherence to 75% of the program will be deemed acceptable | 5 months | |
Primary | Total Participants Completing the Intervention | Adherence to 75% of the program will be deemed acceptable | 2 years | |
Primary | Systolic Blood Pressure | Resting systolic blood pressure, collected in triplicate | 5 months | |
Secondary | Molecular Markers - Acetylcholine-stimulated production of nitric oxide | Serum will be used to perform experiments in which purchased cultured endothelial cells will be exposed to 10% serum from human subjects for 24 hours. The investigators will measure acetylcholine-stimulated production of nitric oxide (NO) in endothelial cells following serum incubation. Serum will be collected via venipuncture performed at the CTRC and stored at -80°C until analysis. | 5 months | |
Secondary | Molecular Markers - Acetylcholine-stimulated basal reactive oxygen species production | Serum will be used to perform experiments in which purchased cultured endothelial cells will be exposed to 10% serum from human subjects for 24 hours. The investigators will measure acetylcholine-stimulated basal reactive oxygen species (ROS) production in endothelial cells following serum incubation. Serum will be collected via venipuncture performed at the CTRC and stored at -80°C until analysis. | 5 months | |
Secondary | Cardiorespiratory Fitness (CRF) will be assessed via estimated VO2max | This will be measured by the Tecumseh Step Test. Participants step on and off an 8" step for 3 min, at a metronome-controlled pace of 24 steps/min. Afterward, they immediately sit down, and heart rate is recorded at 30 s and 1 min after completion (using Polar F4 heart rate monitors). These recovery heart rates are then entered into a predictive formula, along with patient biometric information (age, weight, gender), to calculate an estimated VO2max. | 5 months | |
Secondary | Physical function primarily assessed by the 6MWT | Participants will be instructed to walk as far as possible in a six minute period on an indoor track. | 5 months | |
Secondary | Metabolomics analyses will be performed on blood samples | Metabolomics analyses will be performed on blood samples collected during a standardized aerobic exercise session. Samples will be collected before exercise, immediately after, and after 30 min of recovery. Samples will be collected with patient-centric Tasso+ devices (Tasso, Inc) which minimize the discomfort of collection. | 5 months | |
Secondary | Functional Assessment of Cancer Therapy - General (FACT-G, assessing quality of life) | A 27-item scale commonly used to assess overall quality of life in the general cancer survivor population. Scores range from 0-108 with higher scores indicate higher quality of life. | 5 months | |
Secondary | Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) | A 13-item scale commonly used to assess cancer-related fatigue in cancer survivors. Scores range from 0-52 with higher scores indicate lower levels of fatigue. | 5 months | |
Secondary | Godin Leisure Time Physical Activity Questionnaire | A 6-item scale asking participants the amount of time spent in light, moderate, and vigorous physical activity during the past week. Scores start at 0 with no upper range. Higher scores indicate more minutes of activity per week. | 5 months | |
Secondary | Hospital Anxiety and Depression Scale (HADS) | 14 item scale indicating levels of anxiety and depression in clinical populations. Scores range from 0-21 for anxiety and depression scales. Higher scores indicate higher levels of anxiety and depression. | 5 months | |
Secondary | Cardiac risk factors will be collected from medical history forms | These risk factors will be included in secondary analyses to assess if participants at higher known risk of cardiac disease differ in their response to the intervention. | 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Active, not recruiting |
NCT03617666 -
Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study
|
Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Recruiting |
NCT02507479 -
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT02191930 -
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
|
Phase 2 | |
Completed |
NCT01943682 -
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
|
Phase 1 | |
Completed |
NCT01393106 -
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
|
Phase 2 | |
Terminated |
NCT00992030 -
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
|
Phase 3 | |
Terminated |
NCT00722865 -
Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma
|
Phase 2 | |
Unknown status |
NCT00598624 -
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Completed |
NCT03242902 -
To Decrease Fatigue With Light Therapy
|
Phase 3 | |
Active, not recruiting |
NCT05205512 -
Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial
|
N/A | |
Recruiting |
NCT03681561 -
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03250962 -
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT04510610 -
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
|
Phase 2/Phase 3 | |
Completed |
NCT06295211 -
Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
|
||
Active, not recruiting |
NCT02256137 -
A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
|
||
Completed |
NCT02432235 -
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
|
Phase 1 |